Old Web
English
Sign In
Acemap
>
authorDetail
>
Andrew Ostrenga
Andrew Ostrenga
University of Mississippi
Medicine
Oncology
Rhabdomyosarcoma
Tyrosine-kinase inhibitor
Pazopanib
2
Papers
6
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Results of the dose-finding phase of ARST 1321 from the Children's Oncology Group and NRG Oncology: Neoadjuvant chemoradiation or radiation therapy +/- pazopanib in non-rhabdomyosarcoma soft tissue sarcomas.
2019
Journal of Clinical Oncology
Yen-Lin Chen
Aaron R. Weiss
Thomas J. Scharschmidt
Yueh Yun Chi
Jennifer M. Black
Edwin Choy
Simon C. Kao
Mark Kayton
Scott H. Okuno
Andrew Ostrenga
R L Randall
Stephanie A. Terezakis
Eduardo Zambrano
Sheri L. Spunt
Douglas S. Hawkins
Dian Wang
Show All
Source
Cite
Save
Citations (2)
Preoperative chemoradiation +/- pazopanib in non-rhabdomyosarcoma soft tissue sarcoma (NRSTS): A report from Children's Oncology Group (COG) and NRG Oncology.
2019
Journal of Clinical Oncology
Aaron R. Weiss
Yueh Yun Chi
Yen-Lin Chen
Edwin Choy
Jessica L. Davis
Julie Fanburg-Smith
Douglas S. Hawkins
Mark Kayton
Lynn Million
Scott H. Okuno
Andrew Ostrenga
R. Lor Randall
Thomas J. Scharschmidt
Joel Sorger
Sheri L. Spunt
Jing Tian
Stephanie A. Terezakis
Dian Wang
Eduardo Zambrano
Jennifer O. Black
Show All
Source
Cite
Save
Citations (4)
1